

- **Name:** Han Jo Kim
 - **Current Position & Affiliation:** Professor /
Soonchunhyang University Cheonan Hospital
 - **Country:** Korea
-
- **Educational Background:**
 1. University
 - 1) Premedical Course
Soonchunhyang University College of Medicine, Asan, Korea (1996.3-1998.2)
 - 2) M.D.
Soonchunhyang University College of Medicine, Asan, Korea (1998.3-2002.2)
 - 3) M.S.
Graduate school, Soonchunhyang University College of Medicine, Seoul, Korea (2006.3-2008.2.)
 - **Professional Experience:**
 1. Professor
Department of Internal medicine, Soonchunhyang University of College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea (2023.9 – Present)
 2. Assistant Professor, Associate Professor
Department of Internal medicine, Soonchunhyang University of College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea (2013.9 – 2023.8)
 3. Instructor
Department of Internal medicine, Soonchunhyang University of College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea (2010.3 - 2013.8)
 4. Clinical Fellow
Soonchunhyang University of College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea (2009.3 - 2010.2)
 5. Resident in Internal Medicine
Soonchunhyang University of College of Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea (2005.3-2009.2)
 6. Intern
Soonchunhyang University of College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea (2002.3 – 2003.2.)
 - **Professional Organizations:**
 1. Member, Korean Cancer Association
 2. Member, Korean Medical Association
 3. Member, Korean Cancer Study Group (KCSG)
 4. Member, Korean Breast Cancer Society (KBCS)
 5. Member, Korean Society of Medical Oncology (KSMO)
 6. Member, Korean South West Oncology Group (KSWOG)

7. Member, Korean Association of Internal Medicine

• Main Scientific Publications:

1. Review of Antibody-Drug Conjugates. *Korean J Med.* 2023;98(3):108-116.
2. Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer. *Sci Rep.* 2023;19;13(1):9928
3. Eight-Month Follow-up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose. *J Korean Med Sci.* 2023 May 8;38(18):e139.
4. High Expression of Tetraspanin 5 as a Prognostic Marker of Colorectal Cancer. *Int J Mol Sci.* 2023 Mar 30;24(7):6476.
5. Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers. *J Korean Med Sci.* 2023 Apr 3;38(13):e103.
6. High expression of LY6E is an independent prognostic factor of colorectal cancer patients. *Oncol Rep.* 2023 Apr;49(4):80.
7. Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial. *Eur J Cancer.* 2024 Jan;197:113456.
8. Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP. *J Pathol Transl Med.* 2024 Jul;58(4):147-164.
9. Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study. *Lancet Oncol.* 2025 Mar;26(3):343-354.